EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging Issues Regarding the Effects of the Microbiome on Lung Cancer Immunotherapy

Kostas A Papavassiliou iD, Amalia A Sofianidi iD, Fotios G Spiliopoulos iD, Angeliki Margoni iD, Athanasios G Papavassiliou iD

Biomolecules · 2025

DOI: 10.3390/biom15111525 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2025. Verfasst von Kostas A Papavassiliou und 4 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 …. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Microbiota. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the deadliest malignancy, with limited effective and long-term therapeutic options. Immunotherapy has revolutionized the therapeutic landscape of lung cancer. However, not everyone with lung cancer responds to immunotherapy, while, inpatients who temporarily derive clinical benefit, resistance eventually develops. The host microbiome has emerged as a pivotal player in cancer growth and progression. It has been implicated in the intricate connections between immune cells and tumor cells, ultimately augmenting immunotherapy efficacy in solid tumors, while simultaneously mitigating the immune-related adverse events associated with this type of treatment. Notably, lung cancer patients who obtain benefit from immunotherapy have been found to be colonized with specific bacterial populations, and it is this observation that the scientific community is trying to exploit, aspiring to improve lung cancer immunotherapy response rates. Delving deeper into the molecular mechanisms underpinning the effects of the microbiome on immunotherapy is an area that we should pay attention to if we want to utilize microbiome modulation in everyday clinical practice. Fecal microbiota transplantation, probiotics, targeted antibiotic interventions, and dietary modifications are among the strategies that are under investigation in clinical trials, with the ultimate endpoint of lengthening the life expectancy of lung cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsImmunotherapyMicrobiotaHumansProbioticsFecal Microbiota TransplantationAnimals

Stichwörter der Autor:innen

immune checkpoint blockadeimmune checkpoint inhibitorsimmunotherapylung cancermicrobiome

Autor:innen und Institutionen

  • First University Department of Respiratory Medicine, 'Sotiria' Chest Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.

ORCID-Profile: Kostas A Papavassiliou, Amalia A Sofianidi, Fotios G Spiliopoulos, Angeliki Margoni, Athanasios G Papavassiliou

Zitieren

APA

Papavassiliou, K. A., Sofianidi, A. A., Spiliopoulos, F. G., Margoni, A., & Papavassiliou, A. G. (2025). Emerging Issues Regarding the Effects of the Microbiome on Lung Cancer Immunotherapy. Biomolecules. https://doi.org/10.3390/biom15111525

Vancouver

Papavassiliou KA, Sofianidi AA, Spiliopoulos FG, Margoni A, Papavassiliou AG. Emerging Issues Regarding the Effects of the Microbiome on Lung Cancer Immunotherapy. Biomolecules. 2025. doi:10.3390/biom15111525

BibTeX
@article{Papavassiliou2025,
  author = {Papavassiliou, Kostas A and Sofianidi, Amalia A and Spiliopoulos, Fotios G and Margoni, Angeliki and Papavassiliou, Athanasios G},
  title = {Emerging Issues Regarding the Effects of the Microbiome on Lung Cancer Immunotherapy},
  journal = {Biomolecules},
  year = {2025},
  doi = {10.3390/biom15111525}
}
Kostenlos starten →